For complete responders the probability of relapse was 36.5 % at a median follow-up of 24 months ( Figure). The 5-year Event-Free Survival was 49%, median survival 30.5 months. Among the eight pts eligible for ASCT, 6 had effective CD34+ cells harvest and 4 proceeded to transplant. R-GIFOX consisted of Rituximab (375 mg/m2 on day 1), Gemcitabine (1000 mg/m2 on day 2), Oxaliplatin (130 mg/m2 on day 3) and Ifosfamide (5 g/m2 on day 3), as a 24-hour single infusion.
GIFOX DOWNLOAD FULL
Bone marrow tumor clearance after full completion of GIFOX eventually converted 6 CRu in full CR. Download full issue Search ScienceDirect. The ORR according to FDG-PET/IWC criteria after the first 3 courses was 86% (95%CI: +/− 15), with 4 partial and 14 complete responses (8CR+6 CRu= 67% 95%CI: 47–87). Grade 4 thrombocytopenia occurred in 8 pts (38%), grade 4 anemia and grade 3 infection were found in 24% and 33%, respectively.
Like CloudApp, GIFox also makes it very easy for you to share the resultant GIF once it has been created. It supports numerous output formats including GIF, MP4, Web-M and APNG.
GIFOX DOWNLOAD FREE
In two elderly patients Ifo was omitted from the 4 th course onward due to signs of encephalopathy. It is almost a free GIF screen recorder, easy to download and a very useful screen capture tool for GIF, videos and images. This latter event occurred in a 76 yr-old man succumbing to septic shock after the 2 nd cycle of treatment. A total of 105 courses were delivered (median 6, r 2–6) with only three patients receiving less than 4 courses due to disease progression (n=2) and early death (n=1). Fifteen pts (71%) had stage IV disease, nine (43%) had >1 extranodal site, 71% had abnormal LDH, 29% had ECOG PS >1, 43% B-symptoms. Twenty-one pts (M/F=15/6 median age 63 yrs, r 42–80) with PTCL were prospectively accrued. A strict monitoring of Cl cr was required and Ifo doses were reduced according to Kintzel ( Cancer Treat Rev, 1995, 21(1):33-64). For patients > 65 years the agents dosing was determined according to the nadir neutrophil or platelet counts with reduction to 75% of the planned dose for gemcitabine in case of CTCAE v.3 grade 3 toxicity, and for all the three drugs in case of grade 4 toxicity.
No dose reductions were planned in case of inadequate bone marrow recovery, and treatment was delayed until the absolute neutrophil count was more than 1000/μL and the platelet count more than 50000/μL. GIFOX consisted of G 1200 mg/m 2 D1, Ox 120 mg/m 2 D2 and Ifo 5 g/m 2 D2, as a 24h single infusion in pts aged ≤ 65 years, or fractionated over days 2, 3 and 4 in pts aged > 65 years, G-CSF 5 mcg/kg/d DD 7–11 (10 mcg/kg/d, 3rd course until SCs mobilization).
Patients had to receive 6 GIFOX courses at biweekly intervals SCs mobilization and consolidation of chemosensitive response with autologous transplantation (ASCT) were planned after the 3rd and the 6th course, respectively.
0 kommentar(er)
